https://blog.dana-farber.org/insight/2023/05/new-targeted-treatments-emerge-for-gastric-and-esophageal-cancer/
"The therapeutic landscape of gastric and esophageal cancer is really evolving — and evolving rapidly," said Enzinger. Making steps forward. Other molecularly targeted therapies are becoming more widespread in the treatment of gastric and esophageal cancer. For example, HER2, a biomarker that is commonly tested in breast cancer, can also

https://www.mayoclinic.org/medical-professionals/cancer/news/where-we-are-with-gastric-and-esophageal-cancers/mqc-20515097
June 11, 2021. Gastric and esophageal cancers are relatively rare in the U.S., where most patients present with advanced (unresectable, metastatic or both) disease. A key reason for late diagnoses is that symptoms of these cancers are challenging to pinpoint — such as nausea, bloating, dysphagia, indigestion or heartburn — which patients

https://www.mskcc.org/news/breakthrough-people-facing-gastric-and-esophageal
HER2-Negative Gastric and Esophageal Cancer. Most esophageal and gastric cancers are HER2-negative, affecting four out of every five patients. Dr. Janjigian led a large clinical study to help those people as well, which was published in Nature in March 2022. Cecilia Defoe taught high school science and biology in Brooklyn public schools for 15

https://ascopubs.org/doi/10.1200/JCO.22.02331
Gastroesophageal cancers, inclusive of gastric and esophageal cancer and cancers of the gastroesophageal junction (GEJ), are among the most prevalent gastrointestinal malignancies globally. There were over one million new cases, and approximately 769,000 deaths due to gastric cancer in 2020, ranking this disease site fourth and fifth globally

https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.4069
4069 Background: Esophageal and gastric cancer (EC and GC) are two common cancer types that severely impact patients' health. The 5-year survival rate for EC and GC is as low as 19% and 31%, respectively. However, early detection will significantly increase the survival rate: stage-1 EC has a 5-year survival rate of 51%, while for stage-1 GC it's 69%. Invasive screening methods, such as

https://jnccn.org/view/journals/jnccn/19/5.5/article-p639.xml
First-Line Treatment for Esophageal Cancer: KEYNOTE-590. In treatment-naїve advanced esophageal cancer, ICIs also have a role, as demonstrated by the results observed with the addition of pembrolizumab to FU + cisplatin in KEYNOTE-590. 5 This trial included only patients with esophageal cancer of either adenocarcinoma or squamous cell carcinoma histology, and thus is quite informative for the

https://www.dana-farber.org/cancer-care/treatment/gastrointestinal/programs/esophageal-gastric
877-442-3324. REQUEST AN APPOINTMENT. At the Center for Esophageal and Gastric Cancer, our mission is to improve the outcome for patients with esophageal and stomach cancer by advancing national standards of care, using the best therapies available, minimizing complications through collaboration in multi-disciplinary clinics, and developing

https://www.mayoclinic.org/diseases-conditions/esophageal-cancer/symptoms-causes/syc-20356084
Esophageal cancer may not cause symptoms early on. Symptoms of esophageal cancer usually happen when the disease is advanced. Signs and symptoms of esophageal cancer include: Difficulty swallowing. Chest pain, pressure or burning. Coughing or hoarseness.

https://www.saintjohnscancer.org/gastrointestinal/conditions-we-treat/stomach-and-esophagus-cancer/
Types of esophageal cancer. Cancer of the esophagus may distort and block the esophagus and invade surrounding structures. Esophageal cancer treatment is based on the type of cancer, which are identified according to the type of cancer cells that are involved.

https://gi.org/topics/esophageal-cancer/
As the tumor grows, the esophagus becomes more narrowed causing difficulty in swallowing even liquids. Cancer of the esophagus can also cause symptoms of indigestion, heartburn, vomiting and choking. Patients may also have coughing and hoarseness of the voice. Involuntary weight loss is also common. In rare instances, patients may throw up blood.

https://ascopubs.org/doi/10.1200/OP.22.00226
Recent data support incorporation of immune checkpoint inhibitors into the treatment armamentarium for esophageal, gastroesophageal junction, and gastric (esophagogastric) cancer. This practical review focuses on clinical trials that influenced US Food and Drug Administration approvals and treatment guidelines in esophagogastric cancer, including the impact of location, stage, histology, human

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530320/
The results are reported in the setting of esophageal and gastric carcinomas as CPS utilizing the formula: CPS = [# positive PD-L1 cells (tumor cells, lymphocytes, macrophages)/# PD-L1 positive and PD-L1 negative tumor cells] ×100%. CPS is reported as a single number with a maximum score of 100.

https://www.dana-farber.org/cancer-care/types/esophageal-cancer
Esophageal cancer forms in tissues that line the esophagus, which is the hollow, muscular tube that moves food and liquid from the throat down into the stomach. Esophageal cancer starts at the inside lining of the esophagus and spreads through the outer layers as it grows. Esophageal cancer is relatively uncommon in the United States, and it

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556999/
Introduction. Gastric and esophageal cancer (GEC) are common cancers of the upper gastrointestinal tract, with estimates of 1.69 million new cases and 1.31 million deaths in 2020 worldwide, and 47.42% of them occur in China [].Primary preventive measures, such as limiting tobacco and alcohol use and maintaining a healthy lifestyle and diet, have important public health implications for

https://deainfo.nci.nih.gov/advisory/ctac/workgroup/gec/2022-11-09-GECWG-Report.pdf
The Working Group noted the increasing weight of esophageal cancer within the overall morbidity and mortality burden of gastric and esophageal cancer in the US population and recommends support for research on preventive interventions for non-H. pylori-related gastric and esophageal cancers as well.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4087968/
Abstract. Esophageal and gastric cancers are both common and deadly. Patients present most often after disease progression and survival is therefore poor. Due to demographic variability and recent changes in disease incidence, much emphasis has been placed on studying risk factors for both esophageal and gastric cancers.

https://www.nature.com/articles/nrc.2016.24
This Review discusses our current understanding of oesophageal adenocarcinoma and intestinal-type gastric cancer, integrating advances from cell-of-origin studies and comprehensive genomic

https://link.springer.com/article/10.1007/s12254-021-00694-5
Summary. During this year's virtual congress of the European Society of Oncology (ESMO) some practice-changing abstracts were presented. Especially immunotherapy (IO) has found its way into the treatment of esophageal (EC) and gastric cancer (GC) in both the adjuvant and palliative setting. The CheckMate 577 trial, which was presented in EMSO

https://www.nature.com/articles/s41598-017-07071-5
Age, period, and cohort effects on esophageal cancer and gastric cancer mortality, stratified by region and sex. (a-d) In the first row represent age-specific mortality rates in the reference

https://dceg.cancer.gov/news-events/news/2021/par-esophageal-gastric-cancer
Tobacco smoking, obesity, alcohol consumption, and other modifiable risk factors contribute to a large proportion of cases of esophageal and gastric cancers in the U.S., according to a study published April 2021 in the journal, American Journal of Gastroenterology.These findings highlight significant opportunities to reduce the burden of these cancers.

https://digestivecancers.eu/gastric-esophageal-what/
Gastric cancer - also called stomach cancer - is a disease in which cancer cells form in the lining of the stomach. It is the fourth most common cancer in the world. In Europe, around 136 000 people per year are diagnosed with gastric cancer (2020 Data from ECIS). Oesophageal cancer is the thirteenth, while gastric cancer is the sixth most

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142846/
Introduction. Upper gastrointestinal (UGI) cancers, predominantly gastric cancer (GC) and esophageal cancer (EC), are major malignancies in China and worldwide 1, with prognosis remaining poor in many countries without effective screening programs 2,3.Holistic promotion of etiological research and identification of novel biomarkers is essential to ensure implementation of timely and

https://www.frontiersin.org/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers
Research Topics. Part of a multidisciplinary journal, this section focuses on the investigation of tumorigenesis, prevention, early detection and treatment of gastric and esophageal neoplasia.